Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%
- Poor long term growth as Operating profit has grown by an annual rate -18.51% of over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- OPERATING PROFIT(Q) Lowest at HKD -565.11 MM
- PRE-TAX PROFIT(Q) Lowest at HKD -606.34 MM
- NET PROFIT(Q) Lowest at HKD -616.45 MM
2
Risky -
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-25.28%
0%
-25.28%
6 Months
-5.65%
0%
-5.65%
1 Year
43.99%
0%
43.99%
2 Years
145.34%
0%
145.34%
3 Years
130.1%
0%
130.1%
4 Years
110.11%
0%
110.11%
5 Years
106.45%
0%
106.45%
Ascentage Pharma Group International Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
91.26%
EBIT Growth (5y)
-18.51%
EBIT to Interest (avg)
-39.31
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.57
Sales to Capital Employed (avg)
0.15
Tax Ratio
2.64%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
103.00
EV to EBIT
-71.51
EV to EBITDA
-94.80
EV to Capital Employed
40.63
EV to Sales
27.66
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-56.81%
ROE (Latest)
-156.72%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,063.20
245.30
333.43%
Operating Profit (PBDIT) excl Other Income
-309.70
-900.20
65.60%
Interest
69.90
106.10
-34.12%
Exceptional Items
0.30
2.30
-86.96%
Consolidate Net Profit
-439.80
-1,022.90
57.00%
Operating Profit Margin (Excl OI)
-386.30%
-4,018.30%
363.20%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 333.43% vs 0.57% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 57.00% vs 0.37% in Dec 2023
About Ascentage Pharma Group International Co., Ltd. 
Ascentage Pharma Group International Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






